8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A complete, physician-reviewed guide to the FDA approval status of tirzepatide (Mounjaro), the compounding pharmacy rules that apply, and what the current label permits and prohibits.
A detailed comparison of how the FDA and EMA approved and regulate Mounjaro (tirzepatide), including labeling differences, safety monitoring, and post-market surveillance approaches.
A clinician-reviewed analysis of Mounjaro (tirzepatide) safety signals reported to FDA FAERS, including label warnings, real-world adverse event rates, and post-market surveillance findings.
A complete regulatory timeline of Mounjaro (tirzepatide): FDA approval dates, label changes, boxed warnings, post-market safety data, and guidance for prescribers and patients.
A complete guide to Mounjaro (tirzepatide) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market safety surveillance, and ongoing label expansions.
Every FDA label change for Mounjaro (tirzepatide) from initial approval through 2026, including new indications, boxed warnings, safety communications, and post-market requirements.
A clinical review of Mounjaro (tirzepatide) legal battles, patent disputes, FDA approval timeline, label updates, and post-market safety surveillance.
A comprehensive look at Mounjaro (tirzepatide) FDA approval history, current prescribing label, post-market safety surveillance, and the next-generation dual and triple agonist pipeline beyond tirzepatide.